At Stock Options Channel, our YieldBoost formula has looked up and down the VVUS options chain for the new February 2016 contracts and identified one put and one call contract of particular interest. The put …
The Street · 11/24/2015
Call Options
Vivus (NASDAQ:VVUS) are still holding out hope that somehow Carl Icahn will do something compelling that will mean value to this stock, or that somehow the erectile dysfunction drug Stendra (Spedra in Europe) …
Seeking Alpha · BySpencer Osborne · 11/17/2015
s=VVUS SOL Research Package: ... and the S&P 500 closed at 2,089.17, up 0.38%. - Vivus Inc.'s stock slipped by 0.81% to close Friday's session at USD 1.23, below its 50-day and 200-day moving averages of USD 1.
Market Watch · 11/23/2015
More from Bing News
Let’s have a warm look at: VIVUS, Inc. (NASDAQ:VVUS), XenoPort, Inc. (NASDAQ ... The company earning per share $1.82 and 52 week range of the stock remained $41.72 – $60.34, while its day lowest price was $54.63 and its hit its day highest price ...
Techsonian · 11/23/2015
Last month, VVUS shares sank sharply after the company’s stock rating was downgraded by Piper Jaffray. VVUS stock closed at $4.67 per share on Tuesday.
Investor Place · ByChristopher Freeburn · 5/28/2014
Vivus Inc. (VVUS) stock is up over 18% today after the US Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for Stendra. The drug was developed to treat erectile dysfunction (ED) and the recent approval allows for … · 9/19/2014
Many investors appear to be quite bearish on VIVUS, Inc. (VVUS), especially if you look at the percentage of the float that is sold short for this stock. Currently, 35.97% of the float is sold short, suggesting an extreme level of bearishness for VVUS.
Yahoo Finance · 6/3/2014
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is VIVUS Inc. (VVUS - Analyst Report). This biotechnology stock has actually seen estimates rise over the past month for the current fiscal year by ...
ZACKS · 8/31/2015
VIVUS Inc. ( VVUS) was a big mover last session, as the company saw its shares rise roughly 13% on the day. Shares moved up on reports that IEH Biopharma LLC, a subsidiary of activist investor Carl Icahn's Icahn Enterprises L.P., has announced a …
NASDAQ · 9/10/2015